Trials / Completed
CompletedNCT00968591
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
An Open-label, Single-dose Study to Assess the Pharmacokinetics of Oral Everolimus (Afinitor®) in Subjects With Impaired Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This clinical pharmacology research study will assess the safety and pharmacokinetics of the drug everolimus in patients with impaired hepatic function as compared to healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-11-01
- First posted
- 2009-08-31
- Last updated
- 2020-12-21
Locations
3 sites across 3 countries: Germany, Russia, Singapore
Source: ClinicalTrials.gov record NCT00968591. Inclusion in this directory is not an endorsement.